NAD+ Research: Metabolism, Aging and Human Evidence

Raising a blood NAD+ measurement does not by itself establish a health benefit. In a small trial of nicotinamide riboside (NR), blood NAD+ rose without a detected improvement in cognition.^[5] A separate trial of nicotinamide mononucleotide (NMN) found better muscle insulin sensitivity in women with prediabetes, while several other metabolic measures remained unchanged.^[6] Both trials tested NAD+ precursors, not NAD+ itself. The molecule, tissue, and outcome determine what each result can support.

1. NAD+, NADH, NR and NMN are different molecules

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme, not a peptide. Peptides are chains of amino acids; NAD+ has a different chemical structure and participates in enzyme reactions. In energy metabolism, it cycles between the oxidized form, NAD+, and the reduced form, NADH. Their balance helps describe a cell’s metabolic state, while NAD+ also supplies material for other enzyme reactions.^[1][2]

Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are precursors: molecules cells can use in NAD+ synthesis. A 2004 study identified NR kinases in yeast and humans, establishing an enzymatic route from NR toward NAD+.^[1] NMN is another intermediate in this biosynthetic system.^[6]

The names matter when interpreting a paper. An oral NR trial tests a particular NR intervention. It does not establish the effects of administering NAD+ itself, and neither result automatically transfers to a laboratory vial, a different formulation, or a different route of exposure.

2. What aging studies actually measure

In 2015, Zhu and colleagues used phosphorus magnetic resonance spectroscopy to measure NAD metabolites in healthy human brains. Older age was associated with lower NAD+, lower total NAD, and a lower NAD+/NADH ratio.^[2] This was an observational comparison across volunteers. It did not follow each person through decades of aging or test whether increasing NAD+ changed cognition. The findings describe an association in the brain region measured, not a universal rate of NAD+ loss throughout the body.

Animal experiments can examine causes more directly. In a 2016 study, Camacho-Pereira and colleagues found that activity of the NAD-consuming enzyme CD38 increased with age in several mouse tissues. Mice lacking CD38 maintained tissue NAD+ levels as they aged, unlike the comparison animals.^[3] Removing a gene gives researchers a way to test its contribution; it does not reproduce a human supplementation trial.

A 2020 study added a cellular explanation. In mouse tissues and cell experiments, inflammatory signals released by senescent cells increased CD38 expression in macrophages, immune cells that can consume NAD+. The work connected cellular senescence, inflammation, and NAD depletion through a testable mechanism.^[4] Together, these experiments show why researchers study both NAD+ production and its consumption. Adding a precursor addresses one part of that system; it does not by itself demonstrate that every age-related change has been corrected.

3. NR raised blood NAD+ without improving cognition in a pilot trial

A randomized, placebo-controlled pilot published in the 2024 volume of GeroScience studied NR over ten weeks in 20 older adults with mild cognitive impairment. Blood NAD+ increased about 2.6-fold in the NR group, but the investigators did not observe improved cognition on the tests used.^[5]

This is a useful example of a biochemical response and a functional outcome diverging. The blood measurement confirmed that NR changed NAD+ metabolism under the study conditions. It did not establish a cognitive benefit. The authors also reported cerebral blood-flow differences, but noted that these would not survive correction for multiple comparisons. With a small sample and short follow-up, the trial cannot settle whether a different population or longer intervention would yield a different result.^[5]

4. An NMN trial found a specific metabolic effect

A 2021 randomized, double-blind trial studied NMN for ten weeks in 25 postmenopausal women with prediabetes and overweight or obesity. Insulin-stimulated glucose disposal, a measure of muscle insulin sensitivity, improved after NMN, with supporting changes in muscle insulin signaling.^[6]

The effect was narrower than a general improvement in metabolic health. Body composition and several blood measurements did not improve, and the investigators found no corresponding improvement in liver or adipose-tissue insulin sensitivity. Muscle NAD+ content itself did not increase in the sampled biopsies.^[6] The result warrants further investigation of that population and endpoint. It does not establish diabetes prevention, weight loss, longer life, or an equivalent effect from NAD+ itself.

5. Compare the study before comparing the claim

For a new paper, start with four details: the exact molecule, the study population or model, the tissue sampled, and the prespecified outcome. Then check the duration, comparison group, size of the effect, and uncertainty around it. A rise in a blood metabolite, a change in muscle physiology, and a change in cognition answer different questions; grouping them under “NAD+ benefits” obscures the evidence.

Laboratory research also needs a clear distinction between the material being tested and the intervention described in a clinical paper. Record identity, formulation, and analytical documentation before treating two materials as comparable. A Certificate of Analysis helps evaluate a research lot, but it cannot establish clinical effectiveness.

Research use only. This article discusses published research for scientific education. RegeneX materials are intended solely for laboratory investigation and are not for human or animal consumption. The studies cited here do not provide instructions for using those materials in people.

Related reading: Thymosin Alpha-1 research and How to read a Certificate of Analysis.